GENNEX LABORATORIES LTD.

Gennex Laboratories Ltd announced that its subsidiary, Deccan Remedies Limited, has received approval from the Drugs Control Administration, Government of Andhra Pradesh. This approval grants a license for the manufacture of several products, including Caffeine, Duloxetine Hydrochloride, Mebeverine Hydrochloride, Phenylephrine Hydrochloride, Trimebutine Maleate, and Oxyclozanide, under Form 25, valid until May 28, 2028. Additionally, Deccan Remedies received a Test License under Form 29 for manufacturing Ranolazine, Cinnarizine, Sacubitril, and Triclabendazole for examination, test, or analysis purposes, valid for three years. These licenses are for both domestic and export markets.

Gennex Laboratories Limited has submitted its 41st Annual Report for the Financial Year ended March 31, 2026, along with the Notice of the Annual General Meeting (AGM). The AGM is scheduled for Wednesday, September 30, 2026, and will be conducted via Video Conferencing (VC) / Other Audio Visual Means (OAVM). The report includes the Director's Report, Independent Audit Report, Standalone and Consolidated Financial Statements (Balance Sheet, Profit & Loss, Cash Flow), and other relevant documents. Members can access these documents electronically and via the company website. The company is also facilitating remote e-voting for resolutions through NSDL.

Gennex Laboratories Limited announced that its Board of Directors met on September 4, 2026. Key approvals include the Draft Directors'/Board Report for the Financial Year ending March 31, 2026, and the scheduling of the 41st Annual General Meeting (AGM) for September 30, 2026. The AGM will be conducted via video conferencing. The board also appointed Ms. Sweety Kapoor as Scrutinizer and NSDL as the authorized agency for facilitating the AGM and e-voting. The book closure date is set from September 23 to September 30, 2026, with e-voting available from September 27 to September 29, 2026. Additionally, Secretarial and Cost Audit Reports for the year ended March 31, 2026, were reviewed.

Gennex Laboratories Ltd has announced that its Board of Directors meeting is scheduled for September 4, 2026. The primary agenda items include deciding on the conduct of the 41st Annual General Meeting (AGM) for the fiscal year ended March 31, 2026, and appointing a scrutinizer for the AGM if the date is finalized. The meeting will take place at the company's corporate office in Hyderabad. This announcement is made in compliance with SEBI (LODR) Regulations, 2015, and will also be uploaded to the company's website.

Gennex Laboratories Ltd announced its unaudited standalone and consolidated financial results for the quarter ended June 30, 2026. The Board of Directors approved these financial statements, along with the limited review reports from the statutory auditor. The company operates in the 'Bulk Drugs, Bioteck Products and Intermediates' segment. The results were prepared in accordance with Indian Accounting Standards (Ind-AS).

Gennex Laboratories Limited announced the approval of its unaudited standalone and consolidated financial statements for the quarter ended June 30, 2026. The Board of Directors reviewed and approved these results, along with the limited review reports from the statutory auditor. The meeting commenced at 4:00 PM and concluded at 4:40 PM. The company also confirmed that the information has been uploaded to its website.

Gennex Laboratories Ltd has announced that its Board of Directors will convene on August 14, 2026, to consider and approve the Unaudited Financial Statements (Standalone and Consolidated) for the quarter ended June 30, 2026. The meeting will also review the Limited Review Reports from the Statutory Auditor. The trading window, which was closed from July 1, 2026, will reopen 48 hours after the declaration of these financial results. The company will also discuss other business items.

Gennex Laboratories Ltd announced that Premier Fiscal Services Pvt Ltd, a promoter/promoter group entity, has pledged 25,00,000 equity shares. The pledge was created on June 09, 2026, with an expiry date of December 07, 2026, and was facilitated through BMD Securities Limited. This disclosure is made under SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011. Premier Fiscal Services Pvt Ltd holds a total of 5,30,38,000 shares, representing 21.831% of the company's total capital. The pledged shares constitute 5.145% of the total share capital.

Gennex Laboratories Ltd has disclosed that its promoter, Premier Fiscal Services Private Limited, has pledged 25,00,000 equity shares. The pledge was created on June 9, 2026, with Vidya Tradecon Private Limited acting as the beneficiary. This action represents approximately 5.145% of the company's total share capital and 9.61% of the promoter's total holding. The shares are pledged with BMD Securities Limited as the DP. The reason for the pledge is not explicitly detailed but is typical for collateral purposes.

Premier Fiscal Services Pvt Ltd has disclosed the pledging of 25,00,000 equity shares in Gennex Laboratories Limited. The pledge was created on June 9, 2026, in favor of M/s. Vidya Tradecon Pvt. Ltd., with an expiry date of December 7, 2026. This action represents 1.029% of the total share capital and is for availing a business loan. Following this, Premier Fiscal Services' encumbered shares stand at 1,25,00,000, representing 5.145% of the total share capital.